Savara Inc
NASDAQ:SVRA
Savara Inc
Capital Expenditures
Savara Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Capital Expenditures
-$59k
|
CAGR 3-Years
-43%
|
CAGR 5-Years
22%
|
CAGR 10-Years
8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$974m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$523m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$1.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$485.4m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$881.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-10%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Capital Expenditures?
Capital Expenditures
-59k
USD
Based on the financial report for Sep 30, 2024, Savara Inc's Capital Expenditures amounts to -59k USD.
What is Savara Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
8%
Over the last year, the Capital Expenditures growth was 78%. The average annual Capital Expenditures growth rates for Savara Inc have been -43% over the past three years , 22% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet